Rhinitis( ranitidine)

  • Jul 04, 2018

Rhinitis( ranitidine) analogues:

Rhinitis( ranitidine) Instructions:

Manufacturer:

Current rhinitis

substance issuance rhinitis

Who can Rhinitis

  • peptic ulcer and duodenal ulcer in the absence ofH. pylori or if H. pylori eradication is not possible as a prophylactic treatment;
  • GERD( gastro-oesophageal reflux disease);
  • Zollinger-Ellison syndrome;
  • chronic gastritis with increased acid-forming function of the stomach in the stage of exacerbation;
  • nonulcer dyspepsia.

How to use Rhinitis

How to use and dose.

Adults.

Peptic ulcer of the stomach in the absence of H. Pylori or as a prophylactic treatment with the impossibility of eradication H. pylori - 150 mg 2 times a day or 300 mg once a day 4 to 8 weeks. Peptic ulcer of the duodenum in the absence of H. pylori or as a prophylactic treatment with the impossibility of H. pylori eradication - 150 mg twice a day or 300 mg once a day 4 to 6 weeks.

Gastro-esophageal reflux disease( GERD) - 150 mg 4 times a day for 4 to 8 weeks. Supportive therapy with GERH - 150 mg once a day to 12 months.

Zollinger-Ellison syndrome - the initial dose is 150 mg 4 times a day, but if necessary, the dose may be increased. The choice of dose is individual.

For patients with nonulcer dyspepsia, a course of 150 mg 2 times a day for 2 to 4 weeks or 300 mg once a day is recommended.

Chronic gastritis with increased acid-forming function of the stomach in the acute stage - 150 mg twice a day 2 - 4 weeks or 300 mg once a day.

Renal failure

In patients with severe renal disease( creatinine clearance less than 50 mL / min), ranitidine can be cumulated. For such patients, a dose of 150 mg is recommended once a day.

Patients who undergo continuous ambulatory peritoneal dialysis or chronic hemodialysis, ranitidine( 150 mg) should be used immediately after the dialysis session.

Application features.

At the beginning of treatment it is necessary to exclude the possibility of having malignant neoplasms of the stomach, since treatment with ranitidine can mask the symptoms of the development of a tumor in the stomach.

Ranitidine is excreted by the kidneys, because the plasma level of the drug increases in patients with severe kidney damage. The dose of the drug for such patients should be adjusted accordingly.

In the case of rapid withdrawal of the drug may develop a rebound syndrome. If it is necessary to cancel the drug, you should do it gradually.

Do not administer the drug to patients with acute porphyria.

Pregnancy and lactation.

Ranitidine passes through the placenta and enters the breast milk of a woman. Like other drugs, it can be used during pregnancy only in case of emergency. When breast-feeding children, stop taking the drug.

Side effects of Rinita

A small proportion of patients experienced headache and dizziness, drowsiness, anxiety, agitation. There are reports of single cases of hallucinations, primarily in critically ill patients and elderly patients. There have been several reports of reversible blurring of vision, possibly due to a change in the accommodation of the eye.

Dry mouth, constipation or diarrhea, nausea, vomiting, pain, in the abdomen may be observed.

Revolving laboratory parameters are possible in liver function tests. There are individual reports of hepatitis( with jaundice or without), usually negotiable.

The possibility of developing acute pancreatitis has been reported.

Changes in blood, usually circulating( leukopenia, thrombocytopenia, granulocytopenia, aplastic anemia) have occurred in some patients.

Special cases of agranulocytosis or pancytopenia have been reported, sometimes with bone marrow hypoplasia or aplasia.

As with other H2-receptor antagonists, and when using ranitidine, there are some reports of possible arrhythmia( bradycardia or tachycardia, extrasystole), atrioventricular blockages. There are reports of pain in the joints and muscles.

There may be increases in blood cretinin, increased levels of prolactin, gynecomastia, amenorrhea, allopecia.

Allergic reactions are rare: urticaria, angioedema, bronchospasm, anaphylactic shock, pain, in the chest, arterial hypotension.

To whom is contraindicated Rhinitis

  • Hypersensitivity to the drug components.
  • The presence of malignant diseases of the stomach.
  • Severe kidney and liver diseases, liver cirrhosis, with a history of portosystemic encephalopathy.
  • Pregnancy and lactation periods.
  • Child's age( up to 14 years).

Reinite interaction

With the application of standard recommended dosages of ranitidine, the drug does not affect cytochrome P450 - associated with a functional oxidative system in the liver. Accordingly, ranitidine in conventional therapeutic doses does not potentiate the effect of drugs that are inactivated by this enzyme, this applies to diazepam, lignocaine, phenothoin, propranolol, theophylline and warfarin.

With simultaneous use with an antacid, the interval between taking antacids and Rinit should be at least 1-2 hours.

With the simultaneous administration of large doses of sucralfate( 2 g) and ranitidine, the absorption of the latter may decrease. The effect is invisible if the sukrafalt is taken after a 2-hour interval. It is recommended that patients who take non-steroidal anti-inflammatory drugs at the same time as ranitidine are recommended, especially for elderly people and patients with a history of peptic ulcer.

Overdose of Rhinitis

No data are available regarding life-threatening consequences of overdose.

In case of an overdose, it is necessary to rinse the stomach and perform symptomatic therapy.

If necessary, drugs can be removed from the plasma by hemodialysis.